Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
These observations are procedural in nature and will be responded within the stipulated time
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
Subscribe To Our Newsletter & Stay Updated